The Science Behind Mamosure | Pre-Clinical Research & Citations

Patented, Phyto-based scientific breast health care – trusted by doctors & families

The Science Behind MAMOSURE

Research Partners

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) — Tata Memorial Centre, Navi Mumbai
India's foremost cancer research institution, affiliated with Tata Memorial Hospital. ACTREC conducted pre-clinical evaluation of Mamosure's proprietary formulation on established breast cancer cell lines using standardised cytotoxicity assay methodology.1,5

Haffkine Institute for Training, Research and Testing (HITRT), Mumbai
A Government of Maharashtra public health institution, established 1899. Haffkine Institute conducted independent safety and toxicological evaluation of Mamosure's formula in in-vivo models.2

Pre-Clinical Study Results

Study 1 — MCF7 Breast Cancer Cell Line (Hormone Receptor-Positive)

Model: MCF7 — the most widely studied oestrogen-receptor-positive human breast cancer cell line, established at Michigan Cancer Foundation.6
Objective: Evaluate cytotoxic and anti-proliferative effects of Mamosure's formulation.
Method: MTT colorimetric cell viability assay and flow cytometry cell-cycle analysis.5
Findings: Statistically significant cytotoxicity; G0/G1 and G2 phase cell-cycle arrest observed.1
Citation: Data on File. Cytotoxicity study of Mamosure on MCF7 cell line. ACTREC, Tata Memorial Centre, Navi Mumbai. [Internal report — available on request].

Study 2 — MDA-MB-231 (Triple-Negative Breast Cancer Cell Line)

Model: MDA-MB-231 — an aggressive, triple-negative (ER−/PR−/HER2−) human breast cancer cell line; widely used to study high-risk, hard-to-treat breast cancer.7
Objective: Assess efficacy of Mamosure's formulation against triple-negative breast cancer cells.
Method: MTT assay and Annexin V/PI apoptosis assay.5
Findings: Successful apoptosis induction and G0/G1 cell-cycle arrest confirmed.1
Citation: Data on File. Cytotoxicity study of Mamosure on MDA-MB-231 cell line. ACTREC, Tata Memorial Centre, Navi Mumbai. [Internal report — available on request].

Study 3 — In-Vivo Safety and Toxicity Profile

Model: In-vivo animal model; conducted under standard toxicological protocols.
Objective: Establish safety of Mamosure's formulation at relevant dosages.
Findings: Complete absence of cytotoxicity to normal, healthy cells confirmed. No adverse effects observed at evaluated dosages.2
Citation: Data on File. Safety and toxicological evaluation of Mamosure. Haffkine Institute for Training, Research and Testing (HITRT), Mumbai. [Internal report — available on request].

Mechanism of Action

1. Cell-Cycle Regulation

The formulation demonstrated G0/G1 and G2 phase arrest in both MCF7 and MDA-MB-231 cell lines.1 Cell-cycle checkpoints are critical control points in cancer biology; disruption of abnormal cell-cycle progression is a recognised target of phytochemical compounds.3 G0/G1 arrest prevents cells from entering DNA synthesis, while G2 arrest prevents entry into mitosis.

2. Selective Apoptosis Induction

Apoptosis is a form of programmed cell death that serves as a natural barrier to cancer progression.4 Mamosure's formulation triggered apoptosis in both tested breast cancer cell lines while demonstrating no toxicity to normal cells in safety evaluation.1,2 Selective induction of apoptosis in malignant cells is a mechanism shared by several validated plant-derived anti-cancer agents.

3. Immune Effector Function

Pre-clinical evaluation indicated support for immune effector activity.2 Immune effector cells — including NK cells and cytotoxic T-lymphocytes — play a central role in tumour immune surveillance. Phytochemical modulation of immune effector function is an established area of active research.3

Regulatory Status

Mamosure is registered with the Food Safety and Standards Authority of India (FSSAI) as a food supplement. FSSAI registration confirms compliance with India's food safety standards for ingredients, manufacture, and labelling. Mamosure is not approved as a drug or medicine by CDSCO (India), US FDA, EMA, or any other drug regulatory authority.

Patent Status

Mamosure's proprietary formulation is protected by patents granted in multiple countries. Patent protection covers the composition and method of preparation. Patent grant by intellectual property offices does not constitute evidence of clinical efficacy.

References

  1. Data on File. Pre-clinical cytotoxicity and cell-cycle studies of Mamosure on MCF7 and MDA-MB-231 breast cancer cell lines. Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India. [Year — 2016-2026].
  2. Data on File. Safety and toxicological evaluation of Mamosure. Haffkine Institute for Training, Research and Testing (HITRT), Mumbai, India. [Year — 2018-2026].
  3. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1–2):72–79. doi:10.1016/j.jep.2005.05.011
  4. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi:10.1080/01926230701320337
  5. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63. doi:10.1016/0022-1759(83)90303-4
  6. Levenson AS, Jordan VC. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res. 1997;57(15):3071–3078. PMID: 9242428
  7. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 1978;14(11):911–915. doi:10.1007/BF0261612